Abstract | PURPOSE: PATIENTS AND METHODS: Data from patients with LRRC treated with C-ion RT from November 2003 to December 2014 at three institutions were retrospectively analyzed. The endpoints of this clinical trial were overall survival (OS), local control (LC), and acute/late toxicity. RESULTS: A total of 224 patients' data were collected. The prescribed dose was 70.4 Gy (relative biological effectiveness [RBE]-weighted absorbed dose) or 73.6 Gy (RBE) in 16 fractions. The median follow-up period from the initiation of C-ion RT was 62 months (range 6-169 months). The OS rates were 73% (95% confidence interval [CI], 67%-79%) at 3 years and 51% (95%CI 44%-58%) at 5 years. The LC rates were 93% (95%CI 88%-96%) at 3 years, and 88% (95%CI 82%-93%) at 5 years. Grade 3 acute toxicity was observed in three patients: gastrointestinal toxicity (n = 1) and pelvic infection (n = 2). Grade 3 late toxicity was observed in 12 patients: skin reaction (n = 2), gastrointestinal toxicity (n = 2), neuropathy (n = 1), and pelvic infection (n = 7). There was no grade 4 or 5 acute or late toxicity. CONCLUSIONS: This first multi-institutional analysis of C-ion RT for LRRC indicated relatively favorable outcomes with limited toxicities.
|
Authors | Makoto Shinoto, Shigeru Yamada, Masahiko Okamoto, Yoshiyuki Shioyama, Tatsuya Ohno, Takashi Nakano, Kenji Nemoto, Yuka Isozaki, Shohei Kawashiro, Hiroshi Tsuji, Tadashi Kamada |
Journal | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
(Radiother Oncol)
Vol. 132
Pg. 236-240
(03 2019)
ISSN: 1879-0887 [Electronic] Ireland |
PMID | 30360998
(Publication Type: Journal Article, Multicenter Study)
|
Copyright | Copyright © 2018 Elsevier B.V. All rights reserved. |
Topics |
- Adult
- Aged
- Aged, 80 and over
- Female
- Gastrointestinal Tract
(radiation effects)
- Heavy Ion Radiotherapy
(adverse effects, methods)
- Humans
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(radiotherapy)
- Radiation Injuries
(etiology)
- Rectal Neoplasms
(radiotherapy)
- Relative Biological Effectiveness
- Retrospective Studies
- Survival Rate
|